Authors: Davies, Q Perkins, AC Roos, JC Molthoff, CFM Verheijen, RHM Frier, M Kenemans, P Broadhead, T Sopwith, M Symonds, EM

Citation: Q. Davies et al., An immunoscintigraphic evaluation of the engineered human monoclonal antibody (hCTMO1) for use in the treatment of ovarian carcinoma, BR J OBST G, 106(1), 1999, pp. 31-37

Authors: van Zanten-Przybysz, I Molthoff, CFM Visser, GWM Verheijen, RMH Plaizier, MABD Pijpers, R Kenemans, P Roos, JC

Citation: I. Van Zanten-przybysz et al., I-131-labelled chimeric monoclonal antibody MOv18 in ovarian cancer patients: a pilot study, TUMOR TARG, 4(3), 1999, pp. 179-188

Authors: Buijs, WCAM Tibben, JG Boerman, OC Molthoff, CFM Massuger, LFAG Koenders, EB Schijf, CPT Siegel, JA Corstens, FHM

Citation: Wcam. Buijs et al., Dosimetric analysis of chimeric monoclonal antibody cMOv18 IgG in ovarian carcinoma patients after intraperitoneal and intravenous administration, EUR J NUCL, 25(11), 1998, pp. 1552-1561